Objective: Intraventricular hemorrhage (IVH) occurs in up to 25% of very low birth weight (VLBW) preterm neonates. Previous studies found that indomethacin administered in the first 6 h of life reduces the incidence of severe IVH in VLBW neonates and decreases cerebral blood flow, suggesting a decrease in cerebral oxygen delivery. Using near-infrared spectroscopy (NIRS), we monitored cerebral oxygenation before, during and after slow indomethacin infusion in extremely low birth weight (ELBW) neonates to determine whether indomethacin decreases cerebral oxygen saturation and increases cerebral oxygen extraction.
Introduction
Intraventricular hemorrhage (IVH), a complication of prematurity, occurs in up to 25% of very low birth weight (VLBW) preterm neonates and causes significant morbidity and mortality. 1 Given the debilitating consequences of IVH, researchers have actively sought effective measures to prevent this complication in neonates. In the 1980s, animal studies provided evidence that indomethacin substantially reduced IVH in Beagle puppies compared with controls. 2 Subsequently, two large randomized, placebo controlled trials found that indomethacin significantly reduced the incidence of severe IVH. 3, 4 Through its properties as a prostaglandin synthetase inhibitor, indomethacin may prevent IVH by preventing cerebral vasodilation in response to hypercarbia. 5, 6 In animal models as well as in human neonates, indomethacin, administered as a bolus, reduces cerebral blood flow. 5, 7, 8 Using 133-Xenon and Doppler studies, researchers measured a decrease in cerebral blood flow in response to indomethacin administration in preterm neonates. 9, 10 If cerebral blood flow decreases consistently with indomethacin administration, one would expect that cerebral oxygenation would fall following indomethacin administration, which potentially risks long-term harm.
We surmised that if indomethacin decreased cerebral blood flow, cerebral oxygenation would decrease and fractional extraction of oxygen would increase. Using near-infrared spectroscopy (NIRS), we continuously monitored cerebral oxygen saturation in conjunction with systemic oxygen saturation to determine indomethacin's effect on cerebral oxygen extraction in extremely low birth weight (ELBW) neonates.
Methods

Patient population
Study criteria included all neonates admitted whose gestational age was less than 30 weeks with arterial access in place. Study exclusion criteria included a cyanotic congenital heart lesion or suspected viability less than the 72 h study period. Informed consent was provided by a parent either prenatally or shortly after birth. The study was approved by the University of Florida's Institutional Review Board.
Monitoring cerebral oxygenation and oxygen extraction Arterial saturations (SaO 2 ) were monitored (Agilent, Palo Alto, CA, USA) as part of routine care. Furthermore, a cerebral probe was placed centrally across the forehead to monitor regional cerebral oxygen saturations (rSO 2 ) using NIRS INVOS (Somanetics, Troy, MI, USA). At 30 to 60 s intervals, SaO 2 and rSO 2 were recorded in a VitalSync computer (Somanetics, Troy, MI, USA). The sampling interval depended upon the VitalSync model being used for a particular patient. Data from the Agilent monitor and INVOS began recording in VitalSync within the first 6 h of life.
Study design
Per unit protocol, neonates with birth weight less than 1000 g received indomethacin 0.1 mg kg À1 intravenously for IVH prophylaxis shortly after birth. Indomethacin was infused over a minimum of 1 h and maximum of 2 h dependent on the volume to be infused and a convenient infusion pump setting. Neonates did not receive indomethacin if they were greater than 1000 g or if they had any contraindications including thrombocytopenia, coagulopathy or profound hypotension.
The values for SaO 2 and rSO 2 in the hour before infusion, the first hour of infusion and 2 h after the infusion were averaged and compared. Fractional cerebral oxygen extraction was calculated as ((arterial oxygen saturation-regional cerebral oxygen saturation)/ arterial oxygen saturation). Furthermore, the mean arterial pressure (MAP) was compared before and after indomethacin.
As this study was observational in nature, arterial blood gases were not obtained at prescribed times, but rather as determined by the clinical team. We evaluated available pH and partial pressure of carbon dioxide (pCO 2 ) before and after indomethacin.
Statistical analysis
The pre-treatment, during treatment and post-treatment fractional cerebral oxygen extractions were compared using repeated measures analysis of variance. Subgroup analyses using Fisher's exact test were performed to determine whether there were gender or racial differences among those who experienced an increase in extraction compared with those who did not. Paired t-test was used to determine differences in SaO 2 , rSO 2 , MAP, pH and pCO 2 before and after indomethacin. Student's t-test was used to compare differences in gestational age and birth weight between the group that exhibited an increase in extraction and the group that did not. Differences were considered significant with P<0.05. Data analyses were performed using SPSS version 18 (SPSS, Chicago, IL, USA).
Results
Clinical characteristics and outcomes
All patients were born and cared for at Shands Children's Hospital at the University of Florida. Data were collected from 32 patients between September 2008 through June 2010. Two patients did not receive indomethacin by protocol because of concomitant hypotension and another two because of concern for bleeding.
Of the remaining 28 patients who received indomethacin, complete data sets were available on 27 and were included for analysis. Overall, 26 of the patients received mechanical ventilation at the time of indomethacin administration, and 22 received surfactant; 10 of these in the delivery room and the other 12 after admission but before the data collection was commenced. The mean (s.d.) gestational age of study patients was 25.8 (1.7) weeks and birth weight was 782 (125) g. In total, 10 study patients were males and 17 were females. One of our study patients died during the study period from hypoxic respiratory failure. Overall, 5 of the study subjects died and 22 survived to transfer or discharge. Among our study patients, cranial ultrasound information was available on 26 patients. Interpretation by a pediatric radiologist revealed that three had grade I germinal matrix hemorrhages and three had grade II hemorrhages. There were no grade III hemorrhages or parenchymal hemorrhages among study patients.
Patterns of SaO 2 , rSO 2 and MAP We found that the MAP measured from the in-dwelling catheter among neonates who received indomethacin increased on average from 30.4 to 33.3 mm Hg (P-value 0.0035). However, systemic saturations did not change from baseline after indomethacin. Cerebral oxygenation trended downward after indomethacin ( Table 1) .
Patterns of fractional cerebral oxygen extraction
Overall, neonates treated with indomethacin exhibited a large variation in fractional cerebral oxygen extraction at baseline, during infusion and after infusion ( Figure 1) . As a group, the fractional cerebral oxygen extraction changed with indomethacin infusion from a baseline of 0.23 ± 0.11 to 0.22 ± 0.11 during infusion to 0.25±0.10 after infusion (P ¼ 0.004). Post-hoc analysis revealed that the fractional extraction of oxygen increased 9% from baseline to after the infusion (P ¼ 0.034).
Extraction differences
To determine whether other factors have a role in whether oxygen extraction changed after indomethacin, we examined gestational age, gender and race as independent variables in those who showed an increase extraction of at least 0.01 and those who did not. Gestational age, birth weight and gender were not statistically different between infants who exhibited an increased extraction and those who did not. However, Caucasians were more likely than African Americans to exhibit an increased cerebral oxygen extraction after indomethacin (Table 2) .
Arterial blood gases
We evaluated pH and pCO 2 before and after indomethacin and found that they differed significantly ( 
Discussion
In this study, we found an increase in fractional cerebral oxygen extraction in VLBW neonates after indomethacin compared with before administration. Furthermore, our subgroup analysis indicates that responses to indomethacin may differ among racial groups. Our findings in neonates in the first day of life complement those of Keating et al. 11 who reported a similar magnitude increase in fractional cerebral oxygen extraction in neonates being treated for a clinically significant ductus arteriosus at 2 to 11 days old.
In our study, indomethacin infusion during the first day of life appears to decrease cerebral blood flow in ELBW neonates as indicated by a small increase in extraction post infusion. However, the clinical implications of such a small increase are unknown. Lower cerebral blood flow and subsequently lower oxygen delivery over a protracted period could potentially be detrimental to the developing brain, and was a concern of some clinicians when the data about efficacy of its use to prevent IVH became apparent. 12 However, to date, no study has demonstrated an increase in ischemic lesions in neonates due to indomethacin, and in the TIPP (Trial of Indomethacin Prophylaxis in Preterm Infants) trial its use actually may have a role in decreasing white matter injury. 13 A stated goal of the TIPP 4 was to determine 'if prophylaxis with indomethacin confers any long-term benefits that outweigh the risks of drug-induced reductions in renal, intestinal and cerebral blood flow'. The results of that trial support that indomethacin at a dose similar to that used in our current study decreases severe IVH without leading to worse neurodevelopmental outcomes caused by cerebral ischemia in those infants who did not have IVH. However, one must also consider the possibility that this small increase in oxygen extraction reflects a concomitant decrease in cerebral blood flow that may place patients who were not destined to IVH at harm.
Although we found that cerebral extraction increased with indomethacin administration, we acknowledge that the demonstrated decrease in cerebral blood flow could be multifactorial. In our evaluation of other variables, we found that pCO 2 decreased in our study patients from baseline after indomethacin. Prior study has shown that hypocapnia can aggravate the decrease in energy-rich phosphate, impair ischemic brain metabolism and worsen cerebral ischemia.
14 However, the times at which arterial blood gases were obtained varied greatly with baseline arterial blood gases obtained on average 91 min (s.d. 69 min) before indomethacin and post-indomethacin arterial blood gases obtained on average 243 min (s.d. 88 min) after the start of infusion. Thus, the implications of this decrease in pCO 2 after indomethacin are unclear. In addition, our study patients exhibited an increase in blood pressure after indomethacin, which should not result in decreased cerebral blood flow.
Study participants were not randomized to treatment, but were treated if their birth weight fell within the less than 1000-g criteria. Measures of cerebral regional oxygenation by NIRS are limited to a small area of the cortex, and may not reflect decreased blood flow and oxygenation in deeper brain regions. On the basis of our finding that cerebral oxygen extraction increased after indomethacin during a short period of time following infusion, we propose that measurements of oxygen extraction in these infants requires longer monitoring to determine whether this is a prolonged or temporary change. Furthermore, our subgroup analysis suggests that there may be racial differences in extraction between Caucasian and African American infants with indomethacin infusion, warranting further study.
Conclusion
Although indomethacin increases fractional cerebral oxygen extraction 9% in VLBW neonates, most likely reflecting a decrease in cerebral blood flow, the clinical implications of such a small increase are unknown and warrant further study. This alteration in cerebral blood flow may be harmful to the developing brain.
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